PRTH-101,Pembrolizumab
Parthenon Therapeutics,Merck
['solid tumor']
parthenon therapeutics announces data at the american association for cancer research (aacr) annual meeting 2023 on prevalence of immune exclusion in solid tumors to support phase 1 clinical trial of prth-101 
Breaking news from Business Wire